(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Showing 1 - 10 of 15 records.
Provide palliative therapy with MIBG for patients with advanced neuroblastoma Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma ...More
1. Determine the maximum tolerated dose of melphalan when combined with buthionine sulfoximine and followed by autologous bone marrow or peripheral blood stem cell support in children with recurrent high-risk neuroblastoma. 2. Assess the toxic effects of this regimen in these patients. 3. Determine...More
This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma....More
The primary goals of this research study are: To determine the maximum tolerated dose of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™LXS) Oral Powder (4-HPR/LXS oral powder) given orally, BID, for seven consecutive days every three weeks, in patients with recurrent and/or resistant neuroblastoma. To...More
This phase I trial is studying the side effects of giving bevacizumab together with cyclophosphamide and zoledronic acid in treating patients with recurrent or refractory high-risk neuroblastoma....More
This phase I trial is studying the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma....More
This phase I trial is studying the side effects and the best dose of vorinostat when given together with isotretinoin to see how well it works in treating patients with high-risk refractory or recurrent neuroblastoma. ...More
This phase II trial is studying how well biological therapy works when given together with sargramostim and isotretinoin in treating patients with relapsed or refractory neuroblastoma....More
Radioisotope therapy, such as iobenguane I 131, releases radiation that kills tumor cells. Drugs used in chemotherapy, such as carboplatin, etoposide, busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A ...More
This phase I trial studies the side effects and best dose of lenalidomide when given together with monoclonal antibody with or without isotretinoin in treating younger patients with refractory or recurrent neuroblastoma. Drugs used in chemotherapy, such as lenalidomide and isotretinoin, work in dif...More
Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at firstname.lastname@example.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.
The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.